The company said it plans to make Giapreza available for patients in the United States in March.
La Jolla‘s shares rose 4.2 percent to $32.45 in extended trading on Thursday.
The injectable works by increasing blood pressure in adults suffering a shock, a critical condition in which blood pressure drops so low that the brain, kidneys and other vital organs can’t receive enough blood flow to function properly.
There are about 800,000 distributive shock cases in the United States every year, of which about 90 percent are septic shock, the most common form of distributive shock, the company said.
About 300,000 of these cases are not adequately treated with current standard therapy, according to the company’s estimates.
Source & Credits: DailyMail